Evolus' Jeuveau marks the beginning of the end for Botox

Allergan and Sauders have been dreading the arrival of Evolus or another competitor. Well, the time is now. What kind of damage will Evolus do to Botox?

Does Saunders have a good plan in place for Jeuveau? Botox generates 23% of Allergan's revenue. Yes, Evolus isn't able to compete (just yet) in all the indications that Botox can. They will eventually. Cool Sculpting is slowing and I'm scared Botox is next? Layoffs to help the bottom line?

We know the price will be lower. If the data is equal then docs will make the switch. These are scary times for Allergan.

Post A Reply

Report this entire thread

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a thread a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the thread has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.

Big article in the WSJ today about the Botox franchise being under attack from new competitors and how bad that is because Botox is 1/5 of Allergan's total revenue. I would link the article but it is behind a pay wall. The WSJ also took a hit at the business saying this isn't a good time for the company and the stock price has fallen 40% since July 2017. Not good news for Allergan or Botox.

Evolus has already crushed analyst estimates, bringing in sales of $2.3 million since its May 15 launch, beating the average analyst estimate of $450,000!! Doctors want options and patients want cheaper Botox!!

post

Big article in the WSJ today about the Botox franchise being under attack from new competitors and how bad that is because Botox is 1/5 of Allergan's total revenue. I would link the article but it is behind a pay wall. The WSJ also took a hit at the business saying this isn't a good time for the company and the stock price has fallen 40% since July 2017. Not good news for Allergan or Botox.

post

Fierce spoke to an analyst at RBC Capital Markets who ran a survey target to dermatologists. Their results “suggest potential for greater than expected acceptance of Jeuveau,” he wrote in his own note to clients. In the first survey, a group of dermatologists and plastic surgeons said they expected to switch 43% of patients over to the newcomer.

But that number “felt unrealistically high” to Stanicky and his colleagues, so they ran a second study. The results? 61% of physicians rated their willingness to switch away from Botox at a 6 or higher on a scale of 1-10. They indicated they’d be looking for a discount of about 28% to make the change, and half of them said “most” of their patients would be willing to go along with it.

We already know the Jeuveau discount will be over 20% so...

Will Botox or Jeuveau be used in that Groupon your wife bought?

There's your answer.

post

Fierce spoke to an analyst at RBC Capital Markets who ran a survey target to dermatologists. Their results “suggest potential for greater than expected acceptance of Jeuveau,” he wrote in his own note to clients. In the first survey, a group of dermatologists and plastic surgeons said they expected to switch 43% of patients over to the newcomer.

But that number “felt unrealistically high” to Stanicky and his colleagues, so they ran a second study. The results? 61% of physicians rated their willingness to switch away from Botox at a 6 or higher on a scale of 1-10. They indicated they’d be looking for a discount of about 28% to make the change, and half of them said “most” of their patients would be willing to go along with it.

We already know the Jeuveau discount will be over 20% so...

20% savings equals 20% more profit for docs. There's no chance they pass those savings along.

post

Fierce spoke to an analyst at RBC Capital Markets who ran a survey target to dermatologists. Their results “suggest potential for greater than expected acceptance of Jeuveau,” he wrote in his own note to clients. In the first survey, a group of dermatologists and plastic surgeons said they expected to switch 43% of patients over to the newcomer.

But that number “felt unrealistically high” to Stanicky and his colleagues, so they ran a second study. The results? 61% of physicians rated their willingness to switch away from Botox at a 6 or higher on a scale of 1-10. They indicated they’d be looking for a discount of about 28% to make the change, and half of them said “most” of their patients would be willing to go along with it.

We already know the Jeuveau discount will be over 20% so...

post

Loading...


Report this post

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a post a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the post has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.